Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 10/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105794 | 0.89 | GPR119 (0.44) | GPR119MKNK2MKNK1EIF4ECYP2C9 | |
| SCHEMBL10120520 | 0.87 | KDR (0.38) | GPR119MKNK2MKNK1EGFRMAPK13 | |
| SCHEMBL10120569 | 0.81 | EIF4E (0.51) | GPR119MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL10105774 | 0.79 | GPR119 (0.46) | GPR119MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL10108025 | 0.79 | GPR119 (0.43) | GPR119MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL10108022 | 0.78 | GPR119 (0.43) | GPR119MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL10120456 | 0.77 | GPR119 (0.55) | GPR119MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL10105772 | 0.77 | KDR (0.52) | GPR119MKNK2MKNK1EIF4EEGFR | |
| SCHEMBL10105769 | 0.76 | FLT1 (0.49) | GPR119MKNK2EGFR | |
| SCHEMBL10120666 | 0.76 | GPR119 (0.59) | GPR119MKNK2MKNK1EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | GPR119 1/4885MKNK2 1686/4885MKNK1 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.